2022.10.14
The business cooperation between Tasly Pharmaceutical Group Co., Ltd. (“Tasly”) and Mauna Kea Technologies SA (“MKT”) was recently completed. 优德88中国官方网站 assisted Tasly in its establishment of a joint venture with MKT and its subsequent business cooperation.
Tasly is a well-known Chinese pharmaceutical company, and it is committed to being the leading provider of integrated solutions for pharmaceutical and health services in China with a global influence. By combining modern traditional Chinese medicine, chemical medicine and biological innovative medicine, with breakthrough regenerative medicine and 4D integrated health management solutions, Tasly covers all areas of health such as pre-examination, early warning, prevention, diagnosis, treatment and rehabilitation. It provides patients and families with personalized full course integrated medical solutions to meet the diversified needs of individuals, optimize life experience and improve the quality of life.
MKT is a global medical equipment company that manufactures and sells Cellvizio, a real-time in vivo cellular imaging platform, and it is listed on the Euronext N.V. Cellvizio delivers cellular visualization practically anywhere in the human body. The technology enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen, classify indeterminate areas of concern, and guide surgical interventions. Cellvizio can be extensively applied in various medical specialties worldwide and is revolutionizing the way physicians diagnose and treat patients – transforming medicine.
According to the transaction scheme, Tasly and MKT’s joint venture would (1) commercialize specific indications of selected Cellvizio products in China; (2) develop and commercialize the application of Cellvizio products in the field of neurology and neurosurgery worldwide; and (3) manufacture Cellvizio products for the Chinese market. The joint venture will leverage distribution partnerships and its own network of marketing professionals in China to accelerate product marketization.
The negotiation and transaction process of this project was relatively complex and included the promotion and connection of different jurisdictions at home and abroad. It involved handling foreign investment, outbound investment, patents, technology licensing, tax laws and other legal issues, and the project timeline was very tight. As PRC counsel to Tasly, 优德88中国官方网站 cooperated with other intermediaries, and led the drafting, reviewing, revision and negotiation of all the Chinese and English transaction documents. This project also involved the assessment of patent infringement risks associated with multiple target products to be commercialized in China and the United States, which also covered European and Japanese patents. 优德88中国官方网站 was highly recognized and affirmed by the client and other intermediaries for its rigorous and efficient work style.
This project was led by Mr. ZHOU, Feng (Frank), Mr.TAO, Xudong, Dr.WANG, Zhaohui (Zoe)and Ms.WU, Longying (Lora). It was primarily undertaken by partner ZHOU, Feng (Frank), Dr.WANG, Zhaohui (Zoe)and Ms.WU, Longying (Lora) from 优德88中国官方网站’s IP team.
